LFCR Overview

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.

Wall Street analysts forecast LFCR stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFCR is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Lifecore Biomedical Inc revenue for the last quarter amounts to 31.11M USD, increased 25.92

Lifecore Biomedical Inc. EPS for the last quarter amounts to -0.29 USD, decreased -45.28

Lifecore Biomedical Inc (LFCR) has 406 emplpoyees as of March 11 2026.

Today LFCR has the market capitalization of 258.52M USD.